Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New NHI Prices Announced: Anti-ulcer Drugs See 10.5% Price Cut
March 20, 2006
- PMDA to Provide More Consultations by Streamlining Its Operation
March 20, 2006
- Sanofi-aventis Readying for Launch of Plavix
March 20, 2006
- Public Symposium Focuses on Cancer Diagnosis and Treatment
March 20, 2006
- STATISTICS
March 20, 2006
- SEMINAR
March 20, 2006
- Major Products, Major Firms Hit Hard: NHI Price Revision
March 20, 2006
- HUMAN RESOURCES
March 20, 2006
- Industry Must Reject Price Reductions Not Based on Market Prices: JPMA President
March 20, 2006
- Pharmacies to Play a Greater Role: JPA Vice President
March 20, 2006
- Takeda Asks Wholesalers Not to Accept Proposals of Bundling from Pharmacy Chains
March 20, 2006
- JPA Presents Petition Regarding New OTC Drug Marketing System
March 20, 2006
- REGULATORY NEWS IN BRIEF
March 20, 2006
- Bill to Amend PAL Approved by Cabinet
March 20, 2006
- Kowa, Nikken Chemicals to Integrate Operations on Oct. 1
March 20, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 20, 2006
- Shionogi, Galderma Announce Marketing Alliance for Acne Treatment
March 20, 2006
- Micrus Obtains Approval for Its Endovascular Treatment System
March 20, 2006
- Kyorin Switches to Holding Company System
March 20, 2006
- Imatron Japan's Heart Laser Recommended for Approval
March 20, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…